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Abstract 
Background: Hemodialysis (HD) population show a high incidence of sudden death (SD), but few 
data are available on this issue in peritoneal dialysis (PD) patients. Aim of the study was to evaluate 
total and sudden mortality in a cohort of dialysis patients, comparing HD versus PD.  
Methods: Clinical data of 2072 dialysis patients were retrospectively collected. The Hazard Ratio of 
total (HR) and sudden (HRcpRisk) mortality were estimated by Cox, and Fine and Gray regression 
models. 
Results: HD patients had a greater number of comorbidities (p=0.02). Deaths were 626/1823 in HD 
and 62/249 in PD. PD patients had a lower risk of death than HD patients at the start of dialysis (HR 
0.13, 95%CI 0.05-0.33, p-value<0.001), however the advantage decreased with time (HR[linear interaction 
with time]  1.33, 95%CI 1.20-1.46, p-value<0.001). Mortality predictors were left ventricular ejection 
fraction<35% (p-value <0.001), older age (p-value<0.001), ischemic heart disease (p-value=0.01), 
diabetes mellitus (p-value=0.01), previous stroke (p-value=0.02) and atrial fibrillation (p-value=0.02). 
The HR for comorbidities was higher in PD patients and the interaction for dialysis modality was 
significant for ischemic heart disease and atrial fibrillation (p-value=0.01 and 0.03, respectively). SD 
were 84:71 in HD and 13 in PD (12.1% and 22.8% of all causes of death, respectively). A no 
significant risk of SD among PD compared to HD patients was detected (HRcpRisk 1.21, 95%CI 0.66-
2.22, p-value=0.53). SD predictors were older age (p-value=0.03), ischemic heart disease (p-
value=0.02) and left ventricular ejection fraction<35% (p-value=0.04), without interactions for 
treatment. 
Conclusions: HD patients showed a greater presence of comorbidities and reduced survival compared 
to PD patients, however, the incidence of SD does not differ in the two populations.  
 
Key words: hemodialysis, mortality, peritoneal dialysis, regression models, sudden death 
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Introduction 
Cardiovascular disease is the leading cause of death in dialysis patients and sudden death (SD) 
represents a significant proportion of overall mortality in both hemodialysis (HD) and peritoneal 
dialysis (PD) patients. Sudden death accounts for about 37.0% of all causes of death in patients with 
end stage renal disease (ESRD) and for 65.0% of cardiovascular deaths. The rate of cardiac arrest is 
7.3% in HD and 6.0% in PD patients [1]. There is evidence showing that left ventricular ejection 
fraction (LVEF) is the best predictor of total and sudden mortality in patients with cardiac disease, but 
without ESRD [2-4]. Less clear are the factors associated with SD in patients undergoing dialysis. It 
was shown that the high incidence of SD in HD patients could be partly explained by the rapid 
changes of plasma electrolytes related to the intermittent nature of this dialysis technique [5, 6]. 
However, in PD patients factors that can cause SD, despite continuous treatment, are not yet clear and 
few studies were carried out on this topic. Moreover, there are no data comparing the incidence of SD 
in HD patients with those undergoing PD. 
In the last few years several studies comparing the risk of total mortality in HD patients and patients 
on PD were performed. Almost all these studies showed a better survival during the first period from 
the start of dialysis in PD than in HD patients, but it is unclear whether the dialysis modality is 
associated with greater long-term survival [7-12]. 
The purpose of the present study is to assess, in a population of ESRD patients, the relationship 
between the different dialysis modality (HD versus PD) and overall and sudden mortality and to 
identify predictors of outcomes for each dialysis modality. 
 
Methods 
In this Italian multicenter retrospective study all dialysis patients (undergoing HD or PD) referred to 7 
dialysis centers of Lombardy, alive on the 1st of January 2010 or starting dialysis between the 1st 
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January 2010 and the 31th of January 2013 (recruitment time), were enrolled and their clinical charts 
were revised. Patients were considered eligible for the study only if an echocardiogram with a 
measured value of left ventricular ejection fraction was available, either obtained within 6 months 
before recruitment if alive, or 6 months before death if deceased. Information on the presence of the 
following comorbidities was collected: ischemic cardiac disease, diabetes mellitus, previous stroke 
and atrial fibrillation. Death causes were derived from medical records. The presence of an implanted 
cardioverter defibrillator (ICD) was also considered. Sudden death was defined as spontaneous death 
preceded by a sudden loss of consciousness within 1 h after onset of acute symptoms, even in the 
presence of pre-existing heart disease, but with unexpected timing and mode. Nephrologists or 
relatives were interviewed to confirm all cases of SD. Procedures were performed according to the 
Helsinki declaration for ethics treatment of human subjects. 
Statistical analysis 
Study endpoints were: 
a. Overall Survival defined as the time from the start of dialysis to the time of death from any cause 
b. Cause of death 
c. Cause-specific Survival defined as the time from the start of dialysis to the time of SD or other 
cause. 
Survival data of patients starting dialysis before the 1st January 2010 and alive on the 1st of January 
2010 were left-truncated [13]. In other terms these patients were not considered at risk of death during 
the interval time between the beginning of dialysis and 1st of January 2010 (i.e. truncation period). 
Overall Survival distribution was estimated by the product-limit method. A linear time by treatment 
interaction term was introduced in a Cox regression model to demonstrate formally the curvature over 
time of the relative hazard function. The average hazard of death per unit time (i.e. each year 
following dialysis start) was estimated. A fixed-effects meta-regression was fitted to the point and 
standard error estimate of the average hazard of death per unit time. A meta-regression forest plot was 
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used to summarize meta-regression results. The Cox regression model was used to evaluate predictors 
of Overall Survival and to test their interaction with treatment.  
In order to estimate the statistical association between the two cohorts of patients (i.e. HD and PD 
patients) and the specific cause of death (i.e. sudden death) and to identify patient characteristics 
statistically associated to the specific cause of death, a survival analysis in the presence of competing 
risks was performed. The Fine and Gray regression model was used to estimate the cause-specific 
hazard ratio (HRcpRisk).  
In the multivariable Cox and Fine and Gray regression models ICD implantation was considered a 
time-varying treatment. 
Survival status was updated on the 31st of January 2014. Median follow-up and its interquartile range 
(IQ range) were estimated with the reverse Kaplan–Meier method [14]. The C completeness index 
[15] was used in order to quantify the completeness of follow-up at the update of survival status. 
Baseline covariate distributions were summarized using descriptive statistics (median and range for 
continuous variables, and absolute and percentage frequencies for categorical variables). The logistic 
regression model was used to detect imbalances between baseline covariate distributions. 
Statistical analysis was performed using Stata software, version 12.1 (StataCorp. 2011. Stata 
Statistical Software: Release 12. College Station, TX: StataCorp LP). 
(see supplementary material for extended statistical analysis) 
 
Results 
Table 1 shows the characteristics of the study population: 249/2072 (12.0%) patients were on PD. 
There were no significant differences in the prevalence of comorbidities considered, except for atrial 
fibrillation, which was more prevalent in HD patients (Odds Ratio, OR 1.46 95%CI 1.05-2.02, 
P=0.024). Hemodialysis patients had a greater number of comorbidities than those on PD (OR 1.18, 
95%CI 1.02-1.37, p=0.025). Fifty-two patients (2.5%) received an ICD for primary or secondary SD 
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prevention, and 10 of them (19.2%) were PD patients. The median duration of follow-up was 1.76 
years (IQ range 0.79-3.35 years) in HD patients and 1.94 years (IQ range 0.84-3.34 years) in those on 
PD (C completeness index 98% of the potential time of follow-up in HD patients and 99% in PD 
patients). The observed deaths were 688: 626/1823 (34.3%) in HD patients and 62/249 (24.9%) in PD 
patients. One hundred and fifty/626 (24.0%) patients on HD, and 22/62 (35.5%) PD patients died 
from cardiovascular causes. (Table 2)    
Total mortality 
The median survival was 3.16 (95%CI 2.82-3.60) years in HD patients and 5.33 (95%CI 4.05 to 6.04) 
years in patients on PD.  Considering only patients alive at 6 months after starting dialysis [early 
mortality, 13.4% (95%CI 11.3-15.8%) in HD and 4.5% (95%CI 2.2-9.2%) in PD], the prognosis was 
still better in PD patients [3.88 (95%CI 3.55 to 4.36) versus 5.33 (95%CI 4.59-6.92) years]. Figure 1 
shows the survival curves of the two populations: at the start of dialysis the survival of PD patients 
was higher than that of HD patients (Hazard Ratio, HR[at dialysis start]  0.41, 95%CI 0.29-0.60, P-value 
<0.001); however, this advantage tended to decrease with time (HR[linear interaction with time] 1.21, 95%CI 
1.11-1.31, P-value<0.001). (Figure 2, panel a). Because the likelihood-ratio test was not significant 
(χ2=3.64; df=1; P-value=0.06), the quadratic term was removed from the regression model. The 
restricted mean at 8 years showed a weaker advantage in comparison to median survival [3.87 
(95%CI 3.65-4.08) years in HD patients and 4.81 (95%CI 4.27-5.36) years in PD patients; P-value 
<0.001]. 
The analysis relative to the influence of each comorbidity on total mortality in the two cohorts of 
patients is shown in Table 3. In both populations, factors associated with an increased risk of 
mortality were older age, LVEF<35% and the presence of ischemic heart disease, diabetes mellitus, 
previous strokes and atrial fibrillation. The HR for individual comorbidity was higher in patients on 
PD, and the interaction test for dialysis treatment (HD versus PD) was significant for ischemic heart 
disease (P-value<0.001), diabetes mellitus (P-value=0.02) and atrial fibrillation (P-value=0.01).  
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Multivariable analysis confirmed that PD patients had a lower risk of death than HD patients (HR 
0.13, 95%CI 0.05-0.33, P-value<0.001) at the start of dialysis, and that the difference was 
significantly reduced with increasing time (HR[linear interaction with time]  1.33, 95%CI 1.20-1.46, P-value 
<0.001). The independent association between risk of death and older age, ischemic heart disease, 
LVEF<35%, diabetes mellitus, previous stroke and atrial fibrillation was also confirmed. An 
interaction effect between dialysis modality and comorbidities was still present for ischemic heart 
disease (P-value=0.01) and atrial fibrillation (P-value=0.02). (Table 4) 
Sudden death 
During follow-up 84 SD occurred. Sudden death, excluding unknown causes, accounted for 22.8% 
(13/57) of causes of death in PD patients and 12.1% (71/588) in those on HD. There was no 
significant difference in the incidence of SD among patients on HD compared to PD patients, 
although the latter showed an increased risk of 23.0% (HRcpRisk 1.23, 95%CI 0.68-2.23, P-value=0.49) 
(Figure 3). The time from starting dialysis treatment did not significantly affect the HRcpRisk and the 
incidence of SD in either group (P-value[linear interaction with time]=0.19) (Figure 2, panel b). 
Among HD patients who died suddenly, 58/71 (81.7%) had an LVEF>35%, while among PD patients 
who suffered a SD those with preserved LVEF were 7/13 (53.8%; P-value=0.03). Twenty-two/48 
(45.8%) HD patients, in whom the timing of death with respect to the HD session could be 
established, died during the first inter-dialytic interval and 18/48 (37.5%) during the last long inter-
dialytic interval of the week. 
The analysis of the influence of each comorbidity on SD risk in the two cohorts of patients is shown 
in Table 5. Variables associated with a higher incidence of SD in HD patients were older age, 
presence of  LVEF<35%, ischemic heart disease and diabetes mellitus, while in patients on PD, 
reduced LVEF, previous strokes and, slightly, ischemic heart disease were associated with SD. The 
interaction test for dialysis treatment (HD versus PD) was not significant for any of the comorbidities 
considered.    
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Multivariable analysis showed that factors significantly associated with SD were older age, presence 
of  LVEF<35%, ischemic heart disease and, slightly, diabetes mellitus. The difference in SD incidence 
was not significantly influenced by dialysis modality (HRcpRisk 1.21, 95%CI 0.66-2.22, P-value=0.53) 
(Table 6).  
 
 
Discussion 
This study shows that, in an ESRD population, survival is higher in PD than in HD patients. Sudden 
death incidence, however, is not different in the two cohorts of patients and sudden death, when 
considering all causes of death, is relatively more frequent in PD than in HD patients. 
In the literature, data on mortality risk comparing PD with HD are not univocal [11, 12, 16-19]. It is 
likely that patients reaching ESRD due to acute renal failure or having worse clinical conditions are 
preferentially placed on HD. The frailty of these patients may increase early mortality after starting 
renal replacement therapy [20], however in our study the survival of PD patients still remains higher 
compared to HD patients, even after eliminating early mortality from the analysis. Nevertheless, this 
advantage decreases over time from starting dialysis therapy. Moreover, in PD patients, the presence 
of each comorbidity determines an increase in the risk of death for any cause from 2 to 3 times 
compared to HD patients, and this finding is particularly evident for ischemic heart disease and atrial 
fibrillation. This result confirms what had already been observed by other authors [19, 21]. In ESRD 
patients, the presence of diabetes mellitus and poor glycemic control are often associated with several 
clinical complications and with an increase of mortality, particularly in PD patients [22-24]. In 
addition, in the tissues of PD patients, diabetic or not, there is a great deposition of Advanced 
Glycation End products that predispose to the metabolic syndrome [25], a condition associated with 
an increased risk of cardiovascular mortality in this population [26]. Several studies demonstrated that 
in PD patients accelerated atherosclerosis processes are actively present and suggest that 
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atherosclerosis risk is even higher in PD than in HD patients [27-29].  
An increased risk of death in HD patients with atrial fibrillation has been described [30], while there 
are no data on atrial fibrillation and mortality in PD patients. The HD session may trigger episodes of 
atrial fibrillation, particularly of the paroxysmal type [31, 32]. It is possible that, in our study 
population, PD patients had more frequently forms of permanent atrial fibrillation and that this may 
partly justify the higher risk of death associated with the arrhythmia compared to HD patients. Non-
paroxysmal atrial ﬁbrillation, in fact, is usually associated with the presence of cardiac disease and 
with a highly signiﬁcant increase in thromboembolism and death [33]. Moreover, HD patients meet 
their nephrologist three times a week, while PD patients perform clinical checks only monthly. This 
could create a less effective clinical monitoring of cardiovascular disease in the latter population. 
In our population, the incidence of sudden death was independent of dialysis modality and even 
slightly higher in subjects undergoing PD. Data also show that among all causes of death, sudden 
death was about twice as frequent in PD as in HD patients. The reported sudden death incidence is 
49/1,000 patients per year in the HD population and 36/1,000 patient per year in the population on PD 
(1). The factors that lead PD patients to die suddenly could somewhat differ from those that induce 
sudden death in HD patients. A previous study linked sudden death in PD patients with reduced LVEF 
and elevated plasma levels of pro-BNP and troponin T, suggesting an important role of heart failure 
and ischemic heart disease as factors associated with increased sudden mortality [34].  In our 
population, among patients who suffered sudden death, prevalence of subjects with LVEF<35% was 
higher in PD compared to HD patients.  This finding suggests that the presence of severe cardiac 
disease could play an important role in determining sudden death in the PD population, while in HD 
patients factors most closely related to dialysis modality may be relevant. In an Australian population 
a daily variation in the pattern of cardiac deaths was observed in HD patients receiving three dialysis 
sessions per week, but not in PD patients [35]. Sudden death occurs more frequently during the long 
interdialytic interval or after the first HD session of the week [5, 6], and in 50 HD patients having an 
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implanted cardiac monitor, the risk of sudden death and significant arrhythmias was greatest during 
the long interdialytic interval [36]. Moreover, HD sessions themselves can cause cardiac arrest and 
lower concentrations of potassium and calcium in the dialysate are associated with a higher incidence 
of cardiac intradialytic arrest [37, 38]. In agreement with these data, we observed that the majority of 
sudden deaths of our HD patients occurred just before or just after the first HD session of the week. 
All this evidence partly justifies the high sudden death incidence in HD patients, even in those with 
preserved LVEF, but less clear is why sudden mortality is also high in PD patients. The effects of 
intradialytic modifications of the electrolytes on the cardiac action potential have been widely 
investigated in HD patients [39-41], while very few studies have been done regarding possible 
electrolyte disturbances in PD patients and their potential arrhythmogenic effects. However, both HD 
and PD populations show an alteration of potassium handling, even if the electrolyte plasma 
fluctuations differ in relation to different dialysis modalities.  Some authors have shown an excess of 
mortality in PD patients associated with serum potassium disturbances. Torlen et al. described that PD 
patients are more likely to have serum potassium <4 mEq/L compared to HD patients and that there is 
a U-shaped relationship between time-averaged serum potassium and PD patients mortality [42]. 
Recently it was reported that both time-averaged serum potassium and its fluctuation contribute to the 
high death risk in PD patients [43]. These studies allow us to hypothesize that electrolyte 
abnormalities could increase the risk of death also in this population. 
Our study has some limitations being a retrospective study. A treatment selection bias was present, 
because the nephrologist was free to choose the dialysis modality for each patient. Moreover, data on 
plasma concentrations of electrolytes in the two study populations are lacking. However, our data 
show that sudden death is an important clinical problem even in the PD population and not only in 
HD patients and strongly suggest the need to undertake studies with the aim of understanding the 
mechanisms behind this type of death in patients undergoing PD.  
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Ethical statement and Informed consent 
As a retrospective study of de-identified data, the study is not subject to ethical committee approval 
according to Italian regulation. All patients, when they were referred to the dialysis center at the 
beginning of renal replacement therapy, signed a consent for the potential uses of their data. 
anonymously. 
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Figure Legends 
 
Figure 1. Survival curves of patients on hemodialysis (HD) and peritoneal dialysis (PD) 
 
Figure 2.         Annual mortality rates of patients on HD and PD 
   
† First row: annual estimates for patients on HD. Second row: annual estimates for patients on PD 
 
Legend  
 Point and standard error estimates for patients on HD 
 Fixed-effects meta-regression model fitted to the annual estimates for patients on HD 
 Point and standard error estimates for patients on PD 
 Fixed-effects meta-regression model fitted to the annual estimates for patients on PD 
 
Figure 3. Cumulative incidence of sudden death and of death due to other causes of patients on hemodialysis (HD) 
and peritoneal dialysis (PD)  
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Table 1. Characteristics of the study population 
 
  Patients Statistical association 
 HD PD 
Odds Ratio§ 
(95%CI) 
P-value 
Age (years) at dialysis start     
 N 1823 249 
1.05 
(0.96-1.15)° 
0.25  Median 68.6 67.5 
 Range 12.9-94.4 23.2-87.1 
Gender      
Female N (%) 681 (37.4) 95 (38.2) 1 
0.81 
Male N (%) 1142 (62.6) 154 (61.8) 1.03 (0.79-1.36) 
Left ventricular ejection fraction    
< 35% N (%) 89 (4.9) 19 (7.6) 1 
0.07 
> 35% N (%) 1734 (95.1) 230 (92.4) 1.61 (0.96-2.69) 
Ischemic heart disease 
No N (%) 1182 (64.8) 167 (67.1) 1 
0.49 
Yes N (%) 641 (35.2) 82 (32.9) 1.10 (0.83-1.46) 
Diabetes mellitus 
No N (%) 1325 (72.7) 189 (75.9) 1 
0.28 
Yes N (%) 498 (27.3) 60 (24.1) 1.18 (0.87-1.61) 
Previous ischemic stroke 
No N (%) 1585 (86.9) 222 (89.2) 1 
0.33 
Yes N (%) 238 (13.1) 27 (10.8) 1.23 (0.81-1.88) 
Atrial fibrillation 
No N (%) 1334 (73.2) 199 (79.9) 1 
0.02 
Yes N (%) 489 (26.8) 50 (20.1) 1.46 (1.05-2.02) 
N° of comorbidities    
1.18 
(1.02-1.37) 
0.02† 
0 N (%) 638 (35.0) 116 (46.6) 
1 N (%) 652 (35.8) 64 (25.7) 
2 N (%) 400 (22.0) 53 (21.3) 
3 N (%) 118 (6.5) 15 (6.0) 
4 N (%) 15 (0.8) 1 (0.4) 
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§ Probability modelled is the probability to be assigned to the HD cohort  
° A 10-unit  increase in age was considered 
† Test for trend 
HD:  hemodialysis; PD: peritoneal dialysis 
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Table 2. Follow-up and events 
 
  
Patients 
HD PD 
Sample size N 1823 249 
Number of deaths N (%) 626 (34.3) 62 (24.9) 
Accrual period  1st of January 2010 to 31th of January 2013 
Closing date  31st of January 2014 
Length of follow-up (years) Median 1.76 1.94 
IQ range 0.79-3.35 0.84-3.34 
Completeness of follow-up (C index)  98% 99% 
Causes of death Cachexia N (%)* 153 (26.0) 18 (31.6) 
Sepsis N (%)* 134 (22.8) 11 (19.3) 
Sudden death N (%)* 71 (12.1) 13 (22.8) 
Neoplasia  N (%)* 66 (11.2) 3 (5.3) 
Heart Failure N (%)* 40 (6.8) 8 (14.0) 
Stroke N (%)* 39 (6.6) 1 (1.8) 
Vascular Disease N (%)* 48 (8.2) 1 (1.8) 
Haemorrhage N (%)* 18 (3.1) 0 
Chronic Pulmonary Disease N (%)* 13 (2.2) 1 (1.8) 
Dementia N (%)* 4 (0.7) 0 
Liver cirrhosis N (%)* 2 (0.3) 1 (1.8) 
Unknown N (%) 38 (6.1) 5 (8.1) 
 
HD: hemodialysis; PD: peritoneal dialysis 
* percentage was calculated by excluding unknown causes 
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Table 3. Univariate Cox analysis results on death risk for any cause in the two cohorts 
 Variable Category 
HD  PD  
HR 
95%CI            P-
value 
HR 
95%CI            P-
value 
Age (years) at dialysis 
start 
- 1.69 ° 
1.56-1.83                         
<                 <0.001      
1.67 ° 
1.29-2.15              
<                <0.001 
Test for 
interaction 
Z: - 0.66;  
P-value: 0.51 
Gender Female 1                         0.40         1                        0.50         
Male 0.93 0.79-1.10 1.75 0.99-3.07 
Test for 
interaction 
Z: -2.02;  
P-value: 0.04 
   
Left ventricular ejection 
fraction 
<35% 1 <0.001 1 0.01 
>35% 0.46 0.35-0.60 0.36 0.19-0.68 
Test for 
interaction 
Z: 0.40; 
 P-value: 0.69 
   
Ischemic heart disease No 1 0.01 1 <0.001 
Yes 1.28 1.09-1.50 3.37 2.02-5.61 
Test for 
interaction 
Z: -3.50;  
P-value: <0.001 
   
Diabetes mellitus No 1 0.01 1 <0.001 
Yes 1.29 1.09-1.54 2.70 1.61-4.54 
Test for 
interaction 
Z: -2.35;  
P-value: 0.02 
   
Previous ischemic stroke No 1 <0.001 1 0.01 
Yes 1.47 1.20-1.80 2.58 1.34-4.98 
Test for 
interaction 
Z: -1.71;  
P-value: 0.09 
   
Atrial fibrillation No 1 <0.001 1 <0.001 
Yes 1.49 1.26-1.76 4.20 2.44-7.24 
Test for 
interaction 
Z: -2.66; 
P-value: 0.01 
   
 ° A 10-unit increase in age was considered 
            HD: hemodialysis; PD: peritoneal dialysis 
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Table 4. Multivariate Cox analysis results on death risk for any cause  
 
 
Legend 
* HR at dialysis start; † linear type of dialysis-by-time interaction; ° Time-varying treatment; § a 10-unit increase in age was considered
Characteristics Category HR 95%CI             P-value 
Treatment     
Type of dialysis HD 1  
<0.001 
 PD * 0.13 0.05-0.33 
 HD   1  
<0.001 
 PD † 1.33 1.20-1.46 
ICD implantation ° No 1  
0.59 
 Yes 0.88 0.57-1.38 
Covariates     
Age (years) at dialysis start § - 1.66 1.53-1.80               <0.001 
Left ventricular ejection fraction HD <35% 1  
<0.001 
 >35% 0.52 0.39-0.70 
 PD <35% 1  
  >35% 0.66 0.32-1.33 
 Test for interaction Z: 0.61; P-value: 0.54  
Ischemic heart disease HD No 1  
0.01 
 Yes 1.04 0.88-1.23 
 PD No 1  
  Yes 2.39 1.35-4.23 
 Test for interaction Z: 2.73; P-value: 0.01 
Diabetes mellitus HD No 1  
0.01 
 Yes 1.24 1.04-1.48 
 PD No 1  
  Yes 1.66 0.96-2.84 
 Test for interaction Z: 1.00; P-value: 0.32 
Previous ischemic stroke 
 
HD No 1  
0.02 
 Yes 1.24 1.01-1.52 
 PD No 1  
  Yes 1.98 1.04-3.78 
 Test for interaction Z: 1.36; P-value: 0.17 
Atrial fibrillation HD No 1  
0.02 
  Yes 1.09 0.92-1.29 
 PD No 1  
  Yes 2.06 1.21-3.53 
 Test for interaction Z: 2.23; P-value: 0.03 
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Table 5. Univariate Fine and Gray analysis results on death risk for sudden deaths and not sudden deaths in the two cohorts 
 
Variable Category 
Sudden death Other causes 
HD PD HD PD 
HR 95%CI      P-value HR 95%CI P-value HR 95%CI P-value HR 95%CI P-value 
Age (years) at 
dialysis start 
- 1.22 ° 1.05-1.42 0.01 1.45 ° 0.92-2.31 0.11 1.65 ° 1.51-1.79 <0.001 1.61 ° 1.25-2.08 <0.001 
Test for 
interaction 
Z: -0.78; P-value: 0.43 Z: -0.73; P-value: 0.47 
Gender Female 1  0.90 1  0.10 1  0.35 1  0.27 
Male 1.03 0.63-1.67  3.43 0.80-14.62  0.92 0.77-1.09  1.39 0.78-2.48  
Test for 
interaction 
Z: -1.51; P-value: 0.13 Z: -1.18; P-value: 0.24 
Left ventricular 
ejection fraction 
<35% 1  0.01 1  0.02 1  <0.001 1  0.23 
>35% 0.33 0.17-0.63  0.29 0.10-0.84  0.57 0.42-0.77  0.59 0.25-1.40  
Test for 
interaction 
Z: 0.34; P-value: 0.73 Z: -0.02; P-value: 0.99 
Ischemic heart 
disease 
No 1  <0.001 1  0.05 1  0.17 1  <0.001 
Yes 2.35 1.47-3.77  2.96 0.99-8.85  1.13 0.95-1.34  2.89 1.65-5.06  
Test for 
interaction 
Z: -0.40; P-value: 0.69 Z: -3.08; P-value: 0.01 
Diabetes mellitus No 1  0.01 1  0.65 1  0.220 1  <0.001 
Yes 2.06 1.28-3.31  1.31 0.41-4.18  1.12 0.93-1.36  2.89 1.64-5.10  
Test for 
interaction 
Z: 0.77; P-value: 0.44 Z: -2.76; P-value: 0.01 
Previous ischemic 
stroke 
No 1  0.310 1  0.02 1  0.01 1  0.14 
Yes 1.37 0.75-2.49  4.85 1.24-18.89  1.44 1.16-1.79  1.67 0.84-3.30  
Test for 
interaction 
Z: -1.73; P-value: 0.08 Z: -0.57; P-value: 0.57 
Atrial fibrillation No 1  0.563 1  0.07 1  <0.001 1  <0.001 
Yes 1.16 0.70-1.91  2.72 0.93-7.97  1.50 1.25-1.79  3.17 1.75-5.73  
Test for 
interaction 
Z: -1.41; P-value: 0.16 Z: -1.81; P-value: 0.07 
° A 10-unit increase in age was considered 
 HD: hemodialysis; PD: peritoneal dialysis
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Table 6.  Multivariate Fine and Gray analysis results on death risk for sudden deaths 
Variable Category HRcpRisk 95%CI             P-value 
Treatment     
Type of dialysis HD 1  
0.53 
 PD 1.21 0.66-2.22 
ICD implantation ° No 1  0.68 
 Yes 1.23 0.45-3.34  
Covariates     
Age (years) at dialysis start § - 1.20 ° 1.01-1.42               0.03 
Left ventricular ejection fraction <35% 1  
0.04 
>35% 0.49 0.25-0.96 
Ischemic heart disease No 1  
0.02 
Yes 1.79 1.11-2.88 
Diabetes mellitus No 1  
0.06 
Yes 1.56 0.99-2.46 
Previous ischemic stroke No 1  
0.26 
Yes 1.38 0.79-2.41 
Atrial fibrillation No 1  
0.98 
Yes 1.01 0.62-1.64 
° Time-varying treatment; § a 10-unit increase in age was considered 
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